Sees Austedo achieving $2.5B in sales by 2027. The company is on track to reach 2023 Ajovy revenue guidance of $400M, with $104M net global sales in Q2. Comments taken from Q2 earnings conference call presentation slides.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA:
- Teva Pharamceutical (NYSE:TEVA) Surges After Earnings Report
- Teva Pharmaceutical Industries Limited (TEVA) Q2 Earnings Cheat Sheet
- Mizuho biotech/biopharma analyst to hold analyst/industry conference call
- Teva, Alvotech to expand strategic biosimilars partnership agreement
- Exelixis announces settlement of CABOMETYX patent litigation with Teva